Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes

Journal of Glaucoma
Janet B SerleBenjamin Yerxa

Abstract

5-MCA-NAT, a putative melatonin MT3 receptor agonist, reduced intraocular pressure (IOP) in ocular normotensive rabbit eyes. This study evaluates the effect of topical application of 5-MCA-NAT on IOP in monkey eyes with laser-induced unilateral glaucoma. A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 25-microL drop of 5-MCA-NAT (2%) was applied topically to the glaucomatous eye at 9:30 am and 3:30 pm for 5 consecutive days. IOP was measured hourly for 6 hours beginning at 9:30 am for one baseline day, one vehicle-treated day, and treatment days 1, 3, and 5 with 5-MCA-NAT. Compared with vehicle treatment, twice daily administration of 5-MCA-NAT for 5 days reduced (P < 0.05) IOP from 1 hour to 5 hours after the first dose, and the IOP-lowering effects were shown to last at least 18 hours following administration, based on IOP measurements made after the fourth and eighth doses. The ocular hypotensive effect of 5-MCA-NAT was enhanced with repeated dosing. The maximum reduction (P < 0.001) of IOP occurred at 3 hours after each morning dose, and was 4.0 +/- 0.5 (mean +/- SEM) mm Hg (10%) on day 1, 5.6 +/- 0.8 mm Hg (15%) on day 3, and 7.0 +/- 1.1 mm Hg (19%) on day 5. Adverse ocular or systemic side effects w...Continue Reading

References

Jul 1, 1988·Current Eye Research·J R SamplesA J Lewy
Feb 1, 1994·Ophthalmology·S R ViggianoR F Brubaker
Apr 6, 2001·European Journal of Pharmacology·J PintorA Peral
Dec 19, 2001·Experimental Eye Research·A F Wiechmann, C R Wirsig-Wiechmann
Mar 12, 2003·Life Sciences·Paula A Witt-EnderbyMelissa A Melan
Mar 19, 2003·British Journal of Pharmacology·Jesus PintorAssumpta Peral

❮ Previous
Next ❯

Citations

Feb 3, 2007·Visual Neuroscience·Per O LundmarkDaniel P Cardinali
Jun 28, 2011·Pharmacogenetics and Genomics·Almudena CrookeJesús Pintor
Oct 5, 2007·Annual Review of Pharmacology and Toxicology·Vasilis Vasiliou, Frank J Gonzalez
Jul 5, 2013·Indian Journal of Anaesthesia·Madhuri S Kurdi, Tushar Patel
Sep 15, 2014·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Lucia de Fatima Sobral SampaioClaudio Nahum Alves
Jul 2, 2005·Journal of Glaucoma·Carol A Rasmussen, Paul L Kaufman
Mar 1, 2011·Expert Opinion on Emerging Drugs·Anne J Lee, Ivan Goldberg
Oct 20, 2012·International Journal of Pharmaceutics·Teresa MusumeciGiovanni Puglisi
Sep 11, 2012·Experimental Eye Research·Gianluca TosiniP Michael Iuvone
Mar 3, 2011·Neuroscience Letters·Susana Alcantara-ContrerasGianluca Tosini
Jul 15, 2009·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Lucia de Fatima Sobral Sampaio
Jan 30, 2009·Autonomic Neuroscience : Basic & Clinical·Aránzazu MedieroJesús Pintor
Mar 5, 2008·Progress in Retinal and Eye Research·Allan F Wiechmann, Jody A Summers
Sep 7, 2007·Autonomic Neuroscience : Basic & Clinical·Pilar Alarma-EstranyJesús Pintor
Jan 19, 2007·Pharmacology & Therapeutics·Pilar Alarma-Estrany, Jesús Pintor
Dec 19, 2006·Experimental Eye Research·Per O LundmarkR E Rosenstein
Jul 25, 2009·Journal of Pineal Research·Pilar Alarma-EstranyJesús Pintor
May 25, 2010·Journal of Pineal Research·Ruth E RosensteinDaniel P Cardinali
Nov 24, 2011·Journal of Pineal Research·Almudena CrookeJesús Pintor
Nov 16, 2010·Journal of Pineal Research·Agorastos Agorastos, Christian G Huber
Apr 9, 2010·Journal of Pineal Research·Nicolás A BelforteRuth E Rosenstein
Jan 21, 2015·Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)·Nicola PescosolidoDario Rusciano
Aug 1, 2006·American Journal of Ophthalmology·Christophe ChiquetPhilippe Denis
Nov 19, 2005·Biochemical Pharmacology·François MaillietJean A Boutin
Apr 23, 2005·Progress in Retinal and Eye Research·P Michael IuvoneShyam S Chaurasia
Mar 5, 2016·The Journal of Pharmacology and Experimental Therapeutics·Alejandro Martinez-AguilaJesus Pintor
May 12, 2015·Veterinary Ophthalmology·Pablo H SandeRuth E Rosenstein
Dec 29, 2012·European Journal of Pharmacology·Alejandro Martínez-ÁguilaJesús Pintor
Jan 18, 2006·European Journal of Medicinal Chemistry·Marie-Françoise BoussardJean A Boutin
Dec 30, 2016·Medicine·Jin-Ah LeeUNKNOWN Epidemiologic Survey Committee of the Korean Ophthalmological Society
Jun 29, 2017·Journal of Pineal Research·Almudena CrookeJesús Pintor
Mar 14, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dax viviD, George E Bentley
Aug 4, 2018·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Lisa A Ostrin
Mar 29, 2019·American Journal of Veterinary Research·Hannah E VisserErin M Scott
Nov 6, 2018·The Journal of Pharmacology and Experimental Therapeutics·Jean A Boutin, Gilles Ferry
Oct 26, 2014·The Journal of Pharmacology and Experimental Therapeutics·Fernando Huete-ToralJesús Pintor
Sep 29, 2019·Acta Oto-laryngologica·Masaya Takumida, Matti Anniko
Nov 7, 2019·Journal of Glaucoma·Lauren CiullaAlon Harris

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.